News & Updates

Ipilimumab plus nivolumab elicits response in mCRPC
Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025 byStephen Padilla

Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).

Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025